IP GROUP
Oxford, UK, 19 February 2015 - Summit (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, announces that at the General Meeting of the Company held earlier today, all the resolutions set out in the Notice of General Meeting that was sent to shareholders on 3 February 2015 were duly passed.
The General Meeting held today follows the announcement by the Company on 2 February 2015 of a proposed listing on the NASDAQ Global Market, proposed US offering of American Depositary Shares, adoption of new Articles of Association and the change of name to Summit Therapeutics plc.
Dr Frank Armstrong, Chairman of Summit commented, "We are pleased with the strong support received from our shareholders at today's meeting. This means Summit is now able to progress to the next stage of the proposed NASDAQ listing and US offering, which is part of our strategy to bring our DMD and CDI candidates to patients and provide greater value for our shareholders."
The details of the proxy votes cast are as follows:
For Against Total Votes % of votes cast in favour
Resolution 1 23,004,630 4,952 23,009,582 99.98%
Resolution 2 23,002,524 6,263 23,008,787 99.97%
Resolution 3 23,005,524 1,952 23,007,476 99.99%
Resolution 4 23,185,116 3,200 23,188,316 99.99%
The proxy forms that gave the Chairman and other Directors discretion have been included in the 'For' total. The total number of proxy votes received represent 56.4% of the Company's issued share capital.
- END -
About Summit
Summit is a drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is quoted on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski (US office)
Tel: +44 (0)1235 443 951
+1 617 294 6607
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson
Tel: +44 (0)20 7148 7900
N+1 Singer (Broker)
Aubrey Powell / Jen Boorer
Tel: +44 (0)20 7496 3000
Peckwater PR
(Financial public relations, UK)
Tarquin Edwards
Tel: +44 (0)7879 458 364
tarquin.edwards@peckwaterpr.co.uk
MacDougall Biomedical Communications (US media contact)
Michelle Avery
Tel: +1 781 235 3060
mavery@macbiocom.com
|
distributed by
|
